Literature DB >> 9844699

[Drug treatment strategies for peripheral obliterative arteriopathy].

H Bounameaux1, R Wütschert.   

Abstract

Peripheral arterial disease of the lower limbs is a manifestation of atherosclerosis, and may also affect other vascular territories such as the coronary and cerebral arteries. Progressive narrowing of the vessels up to total occlusion can present as intermittent claudication or pain at rest, with or without cutaneous lesions. Patients with intermittent claudication are at a low risk of amputation, and the symptom has to be regarded as a warning signal for myocardial infarction and stroke. Nevertheless, if the patient's walking distance is too limited to allow a near-normal life, symptomatic treatment to improve quality of life should be considered. Treatment may consist of walking exercise, surgical or interventional radiological revascularisation, or, in some cases, administration of vasoactive drugs. Antiplatelet agents should be administered in an attempt to limit disease progression and prevent cardiac and cerebrovascular complications, together with active measures to reduce established risk factors such as smoking, diabetes, hyperlipidaemia, and arterial hypertension. The presence of pain at rest indicates that a lower limb is jeopardised, especially when the criteria for critical ischaemia have also been met. These criteria include the presence of chronic (lasting for more than 2 weeks) symptoms of ischaemia at rest and a systolic blood pressure less than 50 mm Hg or 30 mm Hg at the ankle or big toe, respectively. In such a situation, revascularisation should be attempted whenever possible. If this is not possible or if the procedure has failed, prostacyclin administered intravenously for days or weeks is an alternative. After revascularisation, early reocclusion may be prevented by administering anticoagulants and late reocclusion by antiplatelet agents, in conjunction with eradication of risk factors. In all situations, therapeutic decision-making should be undertaken in a multidisciplinary setting and should include the following: specialists in angiology (an internist) and interventional radiology; a vascular surgeon; an orthopaedic surgeon, if necessary; and diabetes and infectious disease specialists.

Entities:  

Mesh:

Year:  1998        PMID: 9844699     DOI: 10.2165/00003495-199856003-00003

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  20 in total

1.  Is it possible to reduce the risk of cardiovascular events in subjects suffering from intermittent claudication of the lower limbs?

Authors:  J P Boissel; J C Peyrieux; J M Destors
Journal:  Thromb Haemost       Date:  1989-09-29       Impact factor: 5.249

2.  Mortality over a period of 10 years in patients with peripheral arterial disease.

Authors:  M H Criqui; R D Langer; A Fronek; H S Feigelson; M R Klauber; T J McCann; D Browner
Journal:  N Engl J Med       Date:  1992-02-06       Impact factor: 91.245

Review 3.  Antithrombotic therapy in peripheral arterial occlusive disease.

Authors:  G P Clagett; W C Krupski
Journal:  Chest       Date:  1995-10       Impact factor: 9.410

4.  The measured effect of stopping smoking on intermittent claudication.

Authors:  C R Quick; L T Cotton
Journal:  Br J Surg       Date:  1982-06       Impact factor: 6.939

5.  Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb.

Authors:  J M Isner; A Pieczek; R Schainfeld; R Blair; L Haley; T Asahara; K Rosenfield; S Razvi; K Walsh; J F Symes
Journal:  Lancet       Date:  1996-08-10       Impact factor: 79.321

6.  Effect of ticlopidine on the long-term patency of saphenous-vein bypass grafts in the legs. Etude de la Ticlopidine après Pontage Fémoro-Poplité and the Association Universitaire de Recherche en Chirurgie.

Authors:  J P Becquemin
Journal:  N Engl J Med       Date:  1997-12-11       Impact factor: 91.245

7.  Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration.

Authors: 
Journal:  BMJ       Date:  1994-01-08

8.  Age at menopause as a risk factor for cardiovascular mortality.

Authors:  Y T van der Schouw; Y van der Graaf; E W Steyerberg; J C Eijkemans; J D Banga
Journal:  Lancet       Date:  1996-03-16       Impact factor: 79.321

9.  Exercise rehabilitation programs for the treatment of claudication pain. A meta-analysis.

Authors:  A W Gardner; E T Poehlman
Journal:  JAMA       Date:  1995-09-27       Impact factor: 56.272

10.  [Double-blind randomized controlled trial of ifenprodil tartrate versus placebo in chronic arterial occlusive disease of the legs at stage II of the Leriche and Fontaine classification].

Authors:  A Branchereau; J Rouffy
Journal:  J Mal Vasc       Date:  1995
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.